Media coverage about Sanofi (NYSE:SNY) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sanofi earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.9768356890339 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern’s rankings:
Shares of Sanofi traded down $0.01, hitting $38.88, during trading hours on Friday, Marketbeat.com reports. 1,302,823 shares of the company’s stock traded hands, compared to its average volume of 1,165,144. Sanofi has a 1 year low of $37.43 and a 1 year high of $50.65. The firm has a market capitalization of $97.54 billion, a PE ratio of 12.42, a price-to-earnings-growth ratio of 1.86 and a beta of 0.84. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.70 and a quick ratio of 1.26.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Friday, April 27th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. The firm had revenue of $7.90 billion during the quarter, compared to analyst estimates of $7.88 billion. Sanofi had a return on equity of 24.45% and a net margin of 10.93%. Sanofi’s quarterly revenue was down 8.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.42 earnings per share. equities research analysts expect that Sanofi will post 3.5 EPS for the current fiscal year.
SNY has been the subject of several recent analyst reports. Barclays lowered Sanofi from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, January 23rd. ValuEngine lowered Sanofi from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Zacks Investment Research lowered Sanofi from a “hold” rating to a “sell” rating in a research report on Tuesday, April 17th. Deutsche Bank restated a “buy” rating on shares of Sanofi in a research report on Monday, March 12th. Finally, Liberum Capital upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, March 23rd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and a consensus price target of $49.33.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.